13 completed, 1 terminated. 14 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 13, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow nalmefene: new trials by email Literature Review of nalmefene trials Research Report on nalmefene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Evaluation of Nalmefene Formulations Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection - Opioid Overdose | Phase 1 | Completed | Knoa Pharma LLC | 13 | 2026-02-06 | 2026-06-05 |
| An Evaluation of The Absolute Bioavailability of TH104 Nalmefene - Healthy | Phase 1 | Completed | Tharimmune Inc | 20 | 2024-01-26 | 2025-04-08 |
| Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg Nalmefene HCl injection, Naloxone HCl intranasal - Opioid Overdose | Phase 1 | Completed | Purdue Pharma LP | 24 | 2022-10-03 | 2025-07-03 |
| Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists Narcan 40 MG/ML Nasal Spray, Naloxone Hydrochloride, Nalmefene HCl injection - Opioid Induced Respiratory Depression, Chronic Opioid Use | Phase 1 | Terminated | Leiden University Medical Center | 58 | 2022-06-24 | 2026-07-29 |
| Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens Nalmefene Hydrochloride - Opioid Overdose | Phase 1 | Completed | Opiant Pharmaceuticals Inc | 24 | 2021-09-01 | 2024-08-05 |
| Pharmacodynamic Evaluation of Intranasal Nalmefene Nalmefene hydrochloride, Naloxone hydrochloride - Pharmacodynamic | Phase 1 | Completed | Opiant Pharmaceuticals Inc | 84 | 2021-03-30 | 2025-07-14 |
| Pharmacokinetic Evaluation of Intranasal Nalmefene Nalmefene Hydrochloride, Nalmefene - Pharmacokinetics | Phase 1 | Completed | Opiant Pharmaceuticals Inc | 68 | 2021-02-08 | 2024-08-13 |
| St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene Low dose naltrexone, Nalmefene - HIV Infection, Alcohol Use | Phase 1 / Phase 2 | Completed | Boston Medical Center | 11 | 2018-07-03 | 2020-08-24 |
| Patient Driven Recovery With Nalmefene and Coaching Nalmefene - Opioid-use Disorder, Harmful; Use, Alcohol | Phase 1 | Completed | Yale University | 10 | 2017-09-01 | 2021-01-22 |
| Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers Nalmefene - Opioid-Related Disorders | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 14 | 2017-06-01 | 2018-03-26 |
| Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation Nalmefene, Placebo - AUD | Phase 1 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 13 | 2016-06-08 | 2026-10-29 |
| A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects nalmefene hydrochloride 10 mg - Alcohol Dependence | Phase 1 | Completed | Otsuka Pharmaceutical Co., Ltd. | 7 | 2016-02-01 | 2017-04-18 |
| Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge Nalmefene 18 mg, then placebo, Placebo, then Nalmefene 18 mg - Alcohol Dependence | Phase 1 | Completed | H. Lundbeck A/S | 22 | 2013-11-01 | 2014-11-11 |
| Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects Nalmefene 18 mg - Renal Impairment | Phase 1 | Completed | H. Lundbeck A/S | 32 | 2013-07-01 | 2016-11-08 |
Opiate Overdose (3) · Alcoholism (2) · Opioid-Related Disorders (2) · Alcohol Drinking (1) · HIV Infections (1) · Pain (1) · Renal Insufficiency (1)
Opiant Pharmaceuticals Inc (3) · H. Lundbeck A/S (2) · Boston Medical Center (1) · Knoa Pharma LLC (1) · Leiden University Medical Center (1) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · National Institute on Drug Abuse (NIDA) (1) · Otsuka Pharmaceutical Co., Ltd. (1) · Purdue Pharma LP (1) · Tharimmune Inc (1) · Yale University (1)
United States (9) · Germany (1) · Japan (1) · Netherlands (1) · Russia (1) · United Kingdom (1)
Debra Kelsh, MD (1) · Ingela Danielsson, MD (1) · Jeffrey H. Samet, MD, MA, MPH (1) · Jun-ichi Hashimoto, PhD (1) · Robert Bass, MD (1) · Rutger van der Schrier, MD (1) · Shawn Searle, MD (1) · Vijay A Ramchandani, Ph.D. (1)
PMID 37496452, PMID 28216062, PMID 33682527, PMID 37530456, PMID 41642634
UH2AA026193 (1)